

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer ID6339

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
Bristol Myers-Squibb (adagrasib)	All Wales Therapeutics and Toxicology Centre
Patient/carer groups	Allied Health Professionals Federation
Asthma and Lung UK Black Health Agency for Equality	 Board of Community Health Councils in Wales
Cancer Black Care	British National Formulary
Cancer Equality	Care Quality Commission
	Department of Health, Social Services
Helen Rollason Cancer Charity Independent Cancer Patients Value Independent Can	•
Independent Cancer Patients Voice Magazillar Cancer Symport	and Public Safety for Northern Ireland
Macmillan Cancer Support Macmillan Cantrage	Healthcare Improvement Scotland Madicines and Usethears products
Maggie's Centres	Medicines and Healthcare products Pagulatory Agency
Marie Curie	Regulatory Agency
Oncogene-Driven Lung Cancer	National Association of Primary Care
Patient Alliance UK	National Pharmacy Association
Roy Castle Lung Cancer Foundation	NHS Confederation
South Asian Health Foundation	Scottish Medicines Consortium
Specialised Healthcare Alliance	Welsh Government
Tenovus Cancer Care	 Welsh Health Specialised Services
UK Lung Cancer Coalition	
	Possible comparator companies
Healthcare professional groups	 Amgen (sotorasib, subject to NICE
 Association of Anaesthetists 	appraisal)
 Association of Cancer Physicians 	 Boehringer Ingelheim (nintedanib)
 Association of Respiratory Nurse 	 Bristol Myers-Squibb (nivolumab)
Specialists	 Hospira (cisplatin, carboplatin,
 Association of Surgeons of Great 	docetaxel)
Britain and Ireland	 Merck Sharp & Dohme
British Geriatrics Society	(pembrolizumab)
British Institute of Radiology	Roche (atezolizumab)
British Oncology Pharmacy	Sandoz (cisplatin)
Association	 Seacross Pharmaceuticals (docetaxel)
British Psychosocial Oncology Society	·
British Society of Interventional	Relevant research groups
Radiology	Cochrane Lung Cancer Group
British Thoracic Oncology Group	Genomics England

Provisional stakeholder list for the evaluation of adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer ID6339 Issue date: July 2024



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 British Thoracic Society British Transplantation Society Cancer Research UK Lung Cancer and Mesothelioma Clinical Expert Group Lung Cancer Nursing UK National Heart and Lung Institute NHS Blood and Transplant Primary Care Respiratory Society Royal College of Anaesthetists Royal College of General Practitioners Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal College of Surgeons Royal College of Surgeons Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers UK Clinical Pharmacy Association UK Oncology Nursing Society Others Department of Health and Social Care NHS England 	 Institute of Cancer Research MRC Clinical Trials Unit National Institute for Health Research Associated Public Health groups Public Health Wales UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.


Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

Provisional stakeholder list for the evaluation of adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer ID6339



The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.